AZD7687 Multiple Ascending Dose Study
Study identifier:D2710C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:2010-019112-21
CTIS identifier:N/A
Study Complete
Official Title
A Phase 1, Single Centre, Single-Blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD7687 after Administration of Multiple Ascending doses in Overweight to Obese but otherwise Healthy Male Subjects
Medical condition
overweight
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD7687, Placebo
Sex
All
Actual Enrollment
45
Study type
Interventional
Age
20 Years - 45 Years
Date
Study Start Date: 01 Apr 2010
Primary Completion Date: 01 Mar 2011
Study Completion Date: 01 Mar 2011
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD7687 Oral suspension, once daily. Starting dose of 1mg and with up to 4 dose escalations. Totally 8 doses. |
| Placebo Comparator: 2 | Drug: Placebo Oral suspension, once daily. Totally 8 doses |
Contacts
Investigators
Principal Investigator
Jan Eriksson
AstraZeneca
